MONHEIM AM RHEIN, Germany, July 09, 2025 / Biotech Newswire / -- Cube Biotech GmbH today announced the appointment of Dr. Joachim Kreuzburg, former CEO and Chairman of the Executive Board of Sartorius AG, to its Board of Directors, effective July 3rd, 2025.
Dr. Kreuzburg brings over two decades of executive leadership in the life sciences industry. During his tenure as CEO of Sartorius (2003–2025), the company expanded from a regional player into a global leader in bioprocessing, growing revenue from approximately €0.5 billion to approximately €3.5 billion and increasing the market capitalization of the group by a factor of approximately 150.
“We are honored to welcome Joachim to the Cube Biotech Board,” said Didier Dargent, Executive Chairman of Cube Biotech. “His strategic insights and deep sector expertise will be invaluable as we scale our global operations and advance our automation-driven capabilities in membrane protein technologies, purification and drug discovery.”
Dr. Kreuzburg added: “Cube Biotech is building a powerful platform with world-class science, strong momentum, and an entrepreneurial team. I am excited to join the Board and support its journey to become a global leader in protein research.”
For high resolution please click the image.
About Dr. Joachim Kreuzburg
Dr. Kreuzburg joined Sartorius in 1999 and served as CEO from 2003 to 2025. He chaired the board of Sartorius Stedim Biotech and currently holds board roles at Carl Zeiss AG, Otto Bock SE & Co. KGaA, and Max Planck Gesellschaft (Germany’s leading research organization).
About Cube Biotech – Pioneering Membrane Protein Production and Purification Technologies
At Cube Biotech, we specialize in the purification, stabilization, and functional screening of membrane proteins — tackling some of the most complex drug targets in biomedical research. As enablers of drug discovery, we support scientists in unlocking the full therapeutic potential of membrane proteins.
Following our merger with IBA Life Sciences and with the strategic support of ARCHIMED, we are accelerating innovation, expanding our global reach, and streamlining services across the entire protein research value chain. Our latest advancement: a proprietary automation technology that enables scalable membrane protein production, providing researchers with the tools to drive structural biology, screening campaigns, and therapeutic development with exceptional efficiency and reproducibility.
Contact
Cube Biotech
Fabian Mohr
Chief Commercial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Leadership; Appointments and Schedules; Joachim Kreuzburg; Drug Discovery; Drug Development; Proteins; Membrane Protein Production; Purification Technologies; Biological Science Disciplines; Cube Biotech; Board of Directors; Sartorius AG; Sartorius Stedim Biotech; life sciences industry; strategic insights; proprietary automation technology; scalable protein production; structural biology; therapeutic development; Germany
Source: Biotech Newswire